Key points from article :
Johnson & Johnson is developing a promising Alzheimer’s drug called Posdinemab, which has earned fast-track designation from the FDA. The drug targets phosphorylated tau, a protein that forms harmful tangles in the brains of Alzheimer’s patients, disrupting brain function and contributing to memory loss.
Posdinemab aims to block the spread of tau between neurons, potentially slowing disease progression. Currently in Phase IIb clinical trials, the study uses innovative plasma biomarkers to identify early-stage patients, reducing reliance on PET scans.
Tau is a critical marker for Alzheimer’s because its levels predict disease progression, and new biomarkers allow researchers to track it before symptoms appear. The trial reflects Johnson & Johnson’s data-driven approach, focusing on individuals with intermediate tau levels to test whether the drug can slow cognitive decline.
Beyond Posdinemab, the company is exploring other treatments and biomarkers, including anti-Tau immunotherapy JNJ-2056, to address the growing global Alzheimer’s crisis.
This work represents hope for millions affected by Alzheimer’s, as Johnson & Johnson strives to transform neurodegenerative care through innovation and dedication.
